Crossmark

What have we learned from observational studies and clinical trials of mild to moderate COPD?

Crossref DOI link: https://doi.org/10.1186/s12931-018-0882-0

Published Online: 2018-09-17

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Barrecheguren, Miriam

González, Cruz

Miravitlles, Marc http://orcid.org/0000-0002-9850-9520
Funding

Funding for this research was provided by:

Esteve Laboratories
License Information

Text and Data Mining valid from 2018-09-17
More Information

Article History

Received: 23 June 2018

Accepted: 5 September 2018

First Online: 17 September 2018

Ethics approval and consent to participate

: Not applicable

: Not applicable

: Marc Miravitlles has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Grifols and Novartis, and consulting fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Gebro Pharma, CSL Behring, Novartis and Grifols.Cruz González has received speaker fees from Novartis, Astra, Boehringer Ingelheim, Chiesi, Menarini, and Rovi, and consulting fees from Astra, Boehringer Ingelheim, Novartis and Esteve.Miriam Barrecheguren has received speaker fees from Grifols and Menarini, and consulting fees from GlaxoSmithKline.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.